红细胞(RBCs)是血液中最丰富的血细胞,从中提取的红细胞膜(RBCM)作为载体因具有体内循环时间长,高载药量,极好的生物相容性及低免疫原性,被作为理想的体内药物运载体应用于肿瘤治疗的研究。使用RBCM包裹载有抗癌药物紫杉醇(PTX)的多孔聚乳酸-羟基乙酸共聚物(PLGA)纳米颗粒,经透射电镜(TEM)可以清楚地观察到RBCM结构包裹在PLGA纳米颗粒表面。采用动态光散射仪(DLS)观察制备的纳米颗粒水动力学粒径,发现RBCM包裹后的纳米颗粒粒径增大约为125±4nm。使用PTX作为模型药物,测得制备的PLGA纳米颗粒载药率约为6.42%,包封率约为96.31%,加入TPGS作为致孔剂,48h体外释药率可以提高到83%。MTT结果表明,RBCM包裹的载药PLGA体系对MCF-7具有很强的杀灭作用。
Red blood cells (RBCs) are the most abundant blood cells.With the long circulation time,high drug loading rate,excellent biocompatibility and low immunogenicity,the extracted red blood cell membrane(RBCM)are used as ideal drug carriers for tumor therapy.Using the red blood cell membrane to encapsulate polylactic acid-glycolic acid copolymer (PLGA) carrying the anticancer drug paclitaxel (PTX) and the pore former vitamin E succinic acid polyethylene glycol ester (TPGS) by squeeze extrusion.Transmission electron microscopy (TEM) can clearly observe that the erythrocyte membrane was wrapped on the surface of PLGA nanoparticles.The dynamic light scattering instrument (DLS) was used to observe the hydrodynamic particle size of the prepared nanoparticles.It was found that the particle size of the nanoparticles after the erythrocyte membrane coating was 125±4nm.Using PTX as a model drug,the prepared drug loading rate of PLGA nanoparticles was about 6.42%,and the encapsulation efficiency was about 96.31%.With the addition of TPGS as a pore forming agent,the in vitro release rate can be increased to 83% after 48h.The MTT results showed that the RBCM-encapsulated drug-loaded PLGA system had a strong inhibitory effect on MCF-7cells.
[1] Sun X,Han X,Xu L,et al.Surface-engineering of red blood cells as artificial antigenpresenting cells promising for cancer immunotherapy[J].Small,2017,13(40):1701864.
[2] Han X,Wang C,Liu Z.Red blood cells as smart delivery systems[J].Bioconjugate Chemistry,2018.
[3] Chambers E,Mitragotri S.Long circulating nanoparticles via adhesion on red blood cells:mechanismand extended circulation[J].Experimental Biology & Medicine,2007,232(7):958.
[4] Mosafer J,Abnous K,Tafaghodi M,et al.In vitro,and in vivo,evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy[J].European Journal of Pharmaceutics & Biopharmaceutics,2017,113:60-74.
[5] Ramazani F,Chen W,van Nostrum C F,et al.Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres:state-of-the-art and challenges[J].International Journal of Pharmaceutics,2016,499(1-2):358.
[6] Zhang K,Tang X,Zhang J,et al.PEG-PLGA copolymers:their structure and structure-influenced drug delivery applications[J].Journal of Controlled Release,2014,183(1):77-86.
[7] Alexandrino E M,Ritz S,Marsico F,et al.Paclitaxel-loaded polyphosphate nanoparticles:a potential strategy for bone cancer treatment[J].Journal of Materials Chemistry B,2014,2(10):1298-1306.
[8] Yang C,Wu T,Qi Y,et al.Recent advances in the application of Vitamin E TPGS for drug delivery[J].Theranostics,2018,8(2):464-485.
[9] Zhu D,Tao W,Zhang H,et al.Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer[J].Acta Biomaterialia,2016,30:144-154.
[10] Guo Y,Luo J,Tan S,et al.The applications of Vitamin E TPGS in drug delivery[J].European Journal of Pharmaceutical Sciences Official Journal of the European Federation for Pharmaceutical Sciences,2013,49(2):175-186.
[11] Aryal S,Hu C M,Fang R H,et al.Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release[J].Nanomedicine,2013,8(8):1271-1280.
[12] Zhang Z,Wang X,Li B,et al.Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy:in vitro and in vivo evaluations[J].Drug Delivery,2018,25(1):166.
[13] Luk B T,Hu C M,Fang R H,et al.Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles[J].Nanoscale,2014,6(5):2730-2737.
[14] Min G,Chao L,Song X,et al.Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy[J].Advanced Materials,2017,29(35):1701429.
[15] Hu C M J,Fang RH,Wang K C,et al.Nanoparticle biointerfacing by platelet membrane cloaking[J].Nature,2015,526(7571):118-121.
[16] Gao W,Fang RH,Thamphiwatana S,et al.Modulating antibacterial immunity via bacterial membrane-coated nanoparticles[J].Nano Letters,2015,15(2):1403.
[17] Zhu H,Chen H,Zeng X,et al.Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance[J].Biomaterials,2014,35(7):2391-2400.
[18] Zhao P,Li L,Zhou S,et al.TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance[J].Materials Science & Engineering C,2018,84:108-117.
[19] Jin Y,Wu Z,Li C,et al.Optimization of weight ratio for DSPE-PEG/TPGS hybrid micelles to improve drug retention and tumor penetration[J].Pharmaceutical Research,2018,35(1):13.
[20] Hu C M,Fang R H,Zhang L.Erythrocyte-inspired delivery systems[J].Advanced Healthcare Materials,2012,1(5):537-547.
[21] Hu C M,Zhang L,Aryal S,et al.Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform[J].Proceedings of the National Academy of Sciences of the United States of America,2011,108(27):10980-10985.
[22] Dehaini D,Wei X,Fang R H,et al.Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization[J].Advanced Materials,2017,29(16):1606209.
[23] Merkel T J,Jones S W,Herlihy K P,et al.Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles[J].Proceedings of the National Academy of Sciences of the United States of America,2011,108(2):586-591.
基金资助
国家自然科学基金资助项目(21303014);中央高校基本科研业务经费,东华-伦敦都市大学中英药用纺织品联合实验室
PDF
(2490KB)
